Canadians seeking new cancer drugs have a longer wait time than those in the United States or Europe, a new report from the Fraser Institute revealed this week.
"Access to New Oncology Drugs in Canada Compared with the United States and Europe" by Dr. Nigel Rawson showed that of 33 new oncology drugs introduced between 2003 and 2011, 30 were approved in the United States, 26 in Europe, and 24 in Canada.
But it goes beyond just accepting new options for treatment. Median review times for new drugs in Canada were almost double that of the U.S. (Europe had the longest review time, at 410 days), and time to market was, on average, 18 months behind the United States.
If you believe this has been sent to you in error, please safely unsubscribe.